

VOLUME 26 - ISSUE 6

December 2021

ISSN: 1092-8529



Cambridge.org/cns

CNS SPECTRUMS

EDITOR-IN-CHIEF: **STEPHEN M. STAHL**



THE JOURNAL OF THE
**Neuroscience
Education Institute**



CAMBRIDGE
UNIVERSITY PRESS

Stahl's Illustrated

Complete your collection at cambridge.org/stahlsillustrated



CNS SPECTRUMS

Special Issue: Functional Neurological Disorder

CONTENTS

EDITORIAL

An agenda for functional neurological disorders: care and research

Karen S. Rommelfanger and Mark Hyman Rapaport 551

LETTER TO THE EDITOR

Defining effective strategies to prevent post-traumatic stress in healthcare emergency workers facing the COVID-19 pandemic in Italy

Claudia Carmassi, Giancarlo Cerveri, Eric Bui, Camilla Gesi, and Liliana Dell'Osso 553

PERSPECTIVES

A framework for understanding the pathophysiology of functional neurological disorder

Daniel L. Drane, Negar Fani, Mark Hallett, Sahib S. Khalsa, David L. Perez, and Nicole A. Roberts 555

REVIEWS

The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia

Konstantinos N. Fountoulakis, Hans-Jurgen Moeller, Siegfried Kasper, Carol Tamminga, Shigeto Yamawaki, Rene Kahn, Rajiv Tandon, Christoph U. Correll, and Afzal Javed 562

Stigma and functional neurological disorder: a research agenda targeting the clinical encounter

Katherine E. MacDuffie, Lindsey Grubbs, Tammyjo Best, Suzette LaRoche, Bridget Mildon, Lorna Myers, Elizabeth Stafford, and Karen S. Rommelfanger 587

Diagnosing functional neurological disorder: seeing the whole picture

Sarah C. Lidstone, Walid Nassif, Jorge Juncos, Stewart A. Factor, and Anthony E. Lang 593

The role of the metabotropic glutamate receptor 5 in nicotine addiction

Funda Akkus, Sylvia Terbeck, Connor J. Haggarty, Valerie Treyer, Janan J. Dietrich, Stefanie Hornschuh, and Gregor Hasler 601

Treatment of functional neurological disorder: current state, future directions, and a research agenda

Kathrin LaFaver, William Curt LaFrance Jr., Michele E. Price, Phyllis B. Rosen, and Mark Rapaport 607

ORIGINAL RESEARCH

Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia

Michael Tocco, John W. Newcomer, Yongcai Mao, Andrei Pikalov, and Antony Loebel 614

Adjunctive treatment with psychostimulants and stimulant-like drugs for resistant bipolar depression: a systematic review and meta-analysis

Evangelia Maria Tsapakis, Antonio Preti, Michael D. Mintzas, and Konstantinos N. Fountoulakis 625

Autistic traits in young adults who gamble

Jon E. Grant and Samuel R. Chamberlain 637

Deconstructing violence in acutely exacerbating psychotic patients

Andrea Nichtová, Jan Volavka, Jan Věvera, Kateřina Přihodová, Veronika Juričková, Anna Klemsová, Marek Páv, Věra Strunzová, Tereza Přihodová, Marcela Nocárová, Eva Papoušková, Petr Žižka, and Lucie Kališová 643

Exploring the clinical profile of problematic pornography use

Campbell Ince, Murat Yücel, Lucy Albertella, and Leonardo F. Fontenelle 648

Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia

Hikaru Hori, Kiyokazu Atake, Asuka Katsuki, and Reiji Yoshimura 658

When neurologists diagnose functional neurological disorder, why don't they code for it?

Lorena DoVal Herbert, Rachel Kim, Asim A.O. Hassan, Alison Wilkinson-Smith, and Jeff L. Waugh 664

Editor-in-Chief

Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA;
Honorary Visiting Senior Fellow at the University of Cambridge, UK.

Field Editors

Bernardo Dell'Osso, University of Milan, Italy
Kostas N. Fountoulakis, Aristotle University of Thessaloniki, Greece
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Donatella Marazziti, University of Pisa, Italy
Humberto Nicolini, National Institutes of Health, Minister of Health, Mexico
Stefano Pallanti, University of Florence, Italy
Thomas E. Schlaepfer, University Hospital Bonn, Germany
Frank I. Tarazi, Harvard Medical School, USA
Carlos A. Zarate, National Institute of Mental Health, USA

Deputy Editor

Thomas L. Schwartz, SUNY Upstate Medical University at Syracuse, USA

Editorial Board

Jagannadha Avasarala, University of South Carolina School of Medicine, USA
Leslie Citrome, New York Medical College, USA
Maria Conceição do Rosario, University of São Paulo Medical School, Brazil
Christoph U. Correll, Hofstra Northwell School of Medicine, USA
Jeffrey L. Cummings, Cleveland Clinic, USA
Thilo Deckersbach, Harvard Medical School, USA
Bernardo Dell'Osso, University of Milan, Italy
Koen Demyttenaere, University Psychiatric Center KuLeuven, Belgium
Karen D. Ersche, University of Cambridge, UK
Nesrin Dilbaz, Üsküdar University NP Brain Hospital, Istanbul
Gianni Faedda, The Mood Disorders Center of New York, USA
Robert L. Findling, Virginia Commonwealth University, USA
Patrick R. Finley, University of California, San Francisco, USA
Kostas N. Fountoulakis, Aristotle University of Thessaloniki, Greece
Mark S. George, Medical University of South Carolina, USA
Ira D. Glick, Stanford University, USA
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Xenia Gonda, Semmelweis University, Hungary
Jon Grant, University of Chicago, USA
Gregor Hasler, University of Berne, Switzerland
Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA
Daphne Holt, Harvard Medical School, USA
Oliver Howes, King's College, London, UK
Peter B. Jones, University of Cambridge, UK
Andres M. Kanner, University of Miami, USA
Antony D. Loebel, New York University School of Medicine, USA
Donatella Marazziti, University of Pisa, Italy
Roger McIntyre, University of Toronto, Canada
Herbert Y. Meltzer, Northwestern University, USA
Philip Mitchell, University of New South Wales, Australia
Mary Moller, Pacific Lutheran University and Northwest Integrated Health, USA
Mark Muse, Muse Psychological Associates, USA
Humberto Nicolini, National Institutes of Health, Minister of Health, México
Andrew A. Nierenberg, Harvard Medical School, USA
Stefano Pallanti, University of Florence, Italy
Katharine A. Phillips, Weill Cornell Medical College, USA
Diego A. Pizzagalli, Harvard Medical School, USA
Mark H. Pollack, Rush University Medical Center, USA
Mark H. Rapaport, University of Utah School of Medicine, USA
Irismar Reis de Oliveira, Federal University of Bahia, Brazil
Trevor W. Robbins, University of Cambridge, UK
Peter P. Roy-Byrne, University of Washington School of Medicine, USA
Barbara J. Sahakian, University of Cambridge, UK
Gerard Sanacora, Yale University School of Medicine, USA
Alan F. Schatzberg, Stanford University School of Medicine, USA
Thomas E. Schlaepfer, University of Bonn, Germany
Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA
Erich Seifritz, University of Zürich, Switzerland
Jordan W. Smoller, Harvard Medical School, USA
Dan J. Stein, University of Cape Town (UCT), South Africa
Stephen Strakowski, University of Texas at Austin, USA
T. Scott Stroup, Columbia University, USA
Frank I. Tarazi, Harvard Medical School, USA
Michael E. Thase, University of Pennsylvania, USA
Michael Trimble, National Hospital for Neurology, Queen Square, London
Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA
John Tully, University of Nottingham, UK
Hiroyuki Uchida, Keio University School of Medicine, Japan
Susan Velasquez, California Department of State Hospitals, USA
Benedetto Vitiello, University of Turin, Italy
Karen Dineen Wagner, The University of Texas Medical Branch, USA
Katherine D. Warburton, California Department of State Hospitals, USA
Stephen R. Wisniewski, University of Pittsburgh, USA
Carlos A. Zarate, Jr., National Institute of Mental Health, USA
Joseph Zohar, Tel Aviv University, Israel

Managing Editor

Lisa Arrington, Cambridge University Press (larrington@cambridge.org)

Aims and Scope

CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to *CNS Spectrums*

All submissions to *CNS Spectrums* should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated *CNS Spectrums* ScholarOne Manuscripts website: <http://mc.manuscriptcentral.com/cnsspectr>

CNS Spectrums will consider and encourage the following types of articles for publication: **Reviews**—The review article is a comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; **Perspectives**—The perspective article is a type of review that is a short, focused summary of a single recent advance, a sort of spotlight on the topic, which could be for example, a single point hypothesis or a novel model. It can stimulate debate and new research. **Meta-guidelines**—A meta-guideline is a “guideline of guidelines” put together by several leading figures in a field in which there are multiple competing guidelines that require synthesis and updating; **Original Research**—Reports the results of a clinical study and contains original research; the journal will also include **Brainstorms** and **Editorials** that shall be commissioned or written by the Editor-in-Chief.

Instructions for Contributors

The Instructions for Contributors are available on Cambridge Core at: <https://www.cambridge.org/core/journals/cns-spectrums/information/instructions-contributors>

Indexing

CNS Spectrums is indexed by *Index Medicus*/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions

Institutional print and electronic: £592/\$938; Institutional electronic only: £450/\$718.

© Cambridge University Press 2021. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: <http://www.cambridge.org/rights/permissions/permission.htm>. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center <http://www.copyright.com>, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking “Request Permissions” within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

CNS Spectrums (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster

Send address changes in the U.S.A., Canada, and Mexico to *CNS Spectrums*, Cambridge University Press, Journals Dept., One Liberty Plaza, 20th Floor, New York, NY 10006, U.S.A. Send address changes elsewhere to *CNS Spectrums*, Cambridge University Press, University Printing House, Shaftesbury Road, Cambridge CB2 8BS, England.

Online availability

CNS Spectrums is hosted on the Cambridge Core service at cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: <http://journals.cambridge.org/>

Reprint and Advertising Sales

Inquiries for bulk reprint sales should be sent to USReprints@cambridge.org. Advertising inquiries should be sent to M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0064; Email: mjmrvica@mrvica.com.